Terug
41
Dagbereik
€ 517,81
€ 537,00
52-Weeksbereik
€ 266,98
€ 548,12
Volume
507.272
50D / 200D Gem.
€ 491,10
/
€ 415,89
Vorige Slotkoers
€ 524,28
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 17,1 | 0,4 |
| P/B | 3,2 | 2,9 |
| ROE % | 19,7 | 3,7 |
| Net Margin % | 41,9 | 3,8 |
| Rev Growth 5Y % | 17,2 | 10,0 |
| D/E | 0,0 | 0,2 |
Belangrijkste Punten
Revenue grew 17,22% annually over 5 years — strong growth
ROE of 19,71% — decent returns on equity
Net margin of 41,94% shows strong profitability
Debt/Equity of 0,00 — conservative balance sheet
Generating 1,04B in free cash flow
Revenue growth is decelerating — 1Y growth trails 5Y average by 6,61%
Groei
Revenue Growth (5Y)
17,22%
Revenue (1Y)10,61%
Earnings (1Y)11,68%
FCF Growth (3Y)17,99%
Kwaliteit
Return on Equity
19,71%
ROIC15,77%
Net Margin41,94%
Op. Margin46,89%
Veiligheid
Debt / Equity
0,00
Current Ratio6,60
Interest Coverage76,54
Waardering
P/E Ratio
17,12
P/B Ratio3,22
EV/EBITDA14,26
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 10,61% | Revenue Growth (3Y) | 16,94% |
| Earnings Growth (1Y) | 11,68% | Earnings Growth (3Y) | 16,42% |
| Revenue Growth (5Y) | 17,22% | Earnings Growth (5Y) | 29,42% |
| Profitability | |||
| Revenue (TTM) | 3,18B | Net Income (TTM) | 1,33B |
| ROE | 19,71% | ROA | 16,94% |
| Gross Margin | 87,92% | Operating Margin | 46,89% |
| Net Margin | 41,94% | Free Cash Flow (TTM) | 1,04B |
| ROIC | 15,77% | FCF Growth (3Y) | 17,99% |
| Safety | |||
| Debt / Equity | 0,00 | Current Ratio | 6,60 |
| Interest Coverage | 76,54 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 17,12 | P/B Ratio | 3,22 |
| P/S Ratio | 7,18 | PEG Ratio | 1,16 |
| EV/EBITDA | 14,26 | Dividend Yield | 0,00% |
| Market Cap | 22,84B | Enterprise Value | 21,29B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 3,18B | 2,88B | 2,33B | 1,94B | 1,69B |
| Net Income | 1,33B | 1,20B | 984,80M | 727,30M | 475,80M |
| EPS (Diluted) | 27,86 | 24,64 | 19,81 | 15,00 | 10,06 |
| Gross Profit | 2,80B | 2,57B | 2,07B | 1,79B | 1,56B |
| Operating Income | 1,49B | 1,38B | 1,18B | 979,70M | 555,90M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 7,88B | 7,36B | 7,17B | 6,04B | 5,17B |
| Total Liabilities | 783,80M | 920,00M | 1,18B | 1,25B | 1,21B |
| Shareholders' Equity | 7,10B | 6,44B | 5,98B | 4,80B | 3,96B |
| Total Debt | 0,0 | 300,00M | 700,00M | 800,00M | 800,00M |
| Cash & Equivalents | 1,56B | 1,70B | 1,21B | 961,20M | 894,80M |
| Current Assets | 3,70B | 3,87B | 3,55B | 3,38B | 2,32B |
| Current Liabilities | 560,60M | 738,10M | 804,40M | 343,20M | 305,40M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Balanced Risk
#103 of 148
Recente Activiteit
Ingestapt
Balanced Risk
Mar 24, 2026